HIV DNA vaccine topical - Genetic Immunity

Drug Profile

HIV DNA vaccine topical - Genetic Immunity

Alternative Names: DermaVir Patch; LC002; Therapeutic DNA dendritic cell vaccine for HIV infections - Genetic Immunity

Latest Information Update: 24 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genetic Immunity LLC
  • Developer Genetic Immunity; Karolinska Institute; National Institute of Allergy and Infectious Diseases; Virostatics
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 24 Jul 2015 DermaVir® is still in active development for HIV-1 infections in Germany, Italy, Sweden, USA and Hungary
  • 18 May 2012 Genetic Immunity plans a phase II trial for Hepatitis C and HIV-1 co-infections
  • 18 May 2012 Genetic Immunity plans a phase IIb trial for HIV-1 infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top